Robert Weigle
About Robert K. Weigle
Independent director of Tenon Medical (TNON), age 64, serving since 2022 with committee experience across Audit, Compensation, and Nominating & Corporate Governance . Background includes CEO roles and senior leadership in medical devices; currently CEO of Prime Genomics (since Oct 2020) and executive in residence at DigitalDX, with earlier executive roles at Benvenue Medical, TherOx, Cardiac Pathways, Baxter Healthcare, Cardima, and experience at Johnson & Johnson . Education: BA in Political Science from the University of California, Berkeley .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Benvenue Medical | CEO and Director | May 2009 – Aug 2020 | Led growth from pre-clinical through clinical and commercial launch; raised over $200M in funding |
| TherOx, Inc. | Senior Executive | Not disclosed | Not disclosed |
| Cardiac Pathways | Senior Executive | Not disclosed | Not disclosed |
| Baxter Healthcare | Senior Executive | Not disclosed | Not disclosed |
| Cardima Corporation | Senior Executive | Not disclosed | Not disclosed |
| Johnson & Johnson | Relevant experience | Not disclosed | Not disclosed |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Prime Genomics | CEO | Oct 2020 – Present | Saliva-based diagnostics company utilizing genomics |
| DigitalDX | Executive in Residence | Not disclosed – Present | Venture capital firm |
| Other public company boards | None disclosed | — | No public company directorships disclosed |
Board Governance
- Independence: Board determined Weigle is independent under Nasdaq rules .
- Committee assignments (current structure): Audit Committee (member), Compensation Committee (member), Nominating & Corporate Governance Committee (member) .
- Chair responsibilities: Nominating & Corporate Governance Committee Chair in FY2024 per director fee schedule .
- Board meeting attendance: FY2024 board met 5 times; each director attended at least 80% of board/committee meetings. FY2023: each director attended at least 83% .
| Year | Board Meetings Held | Attendance Rate (Weigle) |
|---|---|---|
| 2023 | 5 | ≥83% (each director) |
| 2024 | 5 | ≥80% (each director) |
Fixed Compensation
| Metric (USD) | 2023 | 2024 |
|---|---|---|
| Cash Compensation | $67,500 | $75,000 |
| Equity Compensation | $0 | $0 (no director equity in 2024 except initial RSU to Jacques) |
| Total Compensation | $67,500 | $75,000 |
2024 fee breakdown:
| Fee Component | Amount (USD) |
|---|---|
| Board retainer | $40,000 |
| Nominating & Corporate Governance Committee Chair | $10,000 |
| Compensation Committee member | $15,000 |
| Audit Committee member | $10,000 |
Performance Compensation
- Director equity awards: None granted to directors in 2024 (exception: initial RSU grant to Director Kristine Jacques); no performance metrics tied to director compensation disclosed .
| Performance Metric | FY2024 Director Plan Treatment |
|---|---|
| Revenue growth | Not disclosed |
| EBITDA/EBIT | Not disclosed |
| TSR percentile | Not disclosed |
| ESG goals | Not disclosed |
| Option/RSU performance vesting | Not disclosed; no director awards in 2024 (except initial RSU to Jacques) |
Other Directorships & Interlocks
| Company | Role | Committee Roles | Interlocks/Transactions |
|---|---|---|---|
| Public company boards | None disclosed | — | No related-party transactions involving Weigle disclosed |
Expertise & Qualifications
- Medical device operating executive with CEO track record; led Benvenue Medical through clinical and commercial phases; raised over $200M at Benvenue .
- Senior leadership across multiple device firms; venture/innovation exposure via DigitalDX; governance experience through multi-committee service at Tenon .
- Education: BA, Political Science, UC Berkeley .
Equity Ownership
As of June 6, 2025:
| Holding | Shares | Notes |
|---|---|---|
| Common stock beneficially owned | 234 | Less than 1% of voting stock |
| RSUs vesting within 60 days | 78 | Included in beneficial total; time-based vesting |
| Options (exercisable/unexercisable) | None disclosed | — |
| Pledged/hedged shares | None disclosed | No pledging disclosed in beneficial ownership section |
As of June 13, 2024:
| Holding | Shares | Notes |
|---|---|---|
| Common stock beneficially owned | 1,242 | Less than 1% of voting stock |
| RSUs within 60 days | Not disclosed for Weigle | — |
Governance Assessment
- Board effectiveness: Independent status, multi-committee membership (Audit, Compensation, Nominating & Corporate Governance), and chair role in Nominating & Corporate Governance support governance engagement and oversight .
- Attendance: Met or exceeded minimum attendance thresholds in FY2023 (≥83%) and FY2024 (≥80%), indicating consistent engagement .
- Pay structure and alignment: Cash-only director compensation in 2024, modest increases YOY; no performance-linked director equity grants—limits pay-for-performance alignment but reduces risk of misaligned incentives for non-executive directors .
- Ownership “skin in the game”: Very small beneficial ownership (<1%); RSUs indicate some exposure, but overall stake is limited—neutral to slightly negative for alignment, common for micro-cap boards .
- Conflicts and related-party exposure: No related-party transactions involving Weigle; no family relationships or legal proceedings disclosed—clean profile from a conflict-of-interest perspective .
- RED FLAGS: None observed regarding related-party transactions, pledging/hedging, or legal issues; however, low direct ownership may be viewed as weak alignment in some governance frameworks .
Overall signal: Independent, multi-committee contributor with chair responsibilities and reliable attendance; compensation is standard cash-retainer plus committee fees, with no disclosed performance-linked components for directors. No conflicts flagged; ownership is minimal, which may temper alignment optics with shareholders .